4868 RUE LEVY, SUITE 220, SAINT-LAURENT, A8
Reports Third Quarter 2026 Financial Results and Provides Business Update
Investor Presentation
Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Amended material disclosure
Reports Second Quarter 2026 Financial Results and Provides Business Update
2026 Annual Meeting Results - enGene Therapeutics Inc. Shareholder Vote
Annual Report to Security Holders
Q3
Q1
Amended Annual Report
FY 2024
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence